secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001558370-23-002912
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q4 net loss $58.9M, revenue $45.4M; cuts 60 jobs; CSO resigns; UDENYCA AI approved
--------------------------------------------------------------------------------

- Q4 net revenue $45.4M (down from $73.4M YoY); net loss $58.9M ($0.76 per share) vs $45.7M loss in Q4 2021.
- Full year 2022 net revenue $211.0M (down from $326.6M); net loss $291.8M ($3.76 per share).
- Workforce reduction of ~60 employees (~20%) to focus on strategic priorities; expects $3.4M restructuring charges.
- CSO Vladimir Vexler resigned effective March 10, 2023 (or later at his option), not due to disagreement.
- FDA approved UDENYCA autoinjector; toripalimab manufacturing inspection planned for Q2 2023; 2023 opex guidance $315-335M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/chrs-20230302x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer